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PEMBANGUNAN VEKTOR EKSPRESI DAN PENGKLONAN T/A YANG 
NOVEL UNTUK EKSPRESI PRODUK BIOFARMASEUTIKAL 
BERASASKAN PROTIEN YANG EFISIEN DI DALAM Escherichia coli 
 
 
ABSTRAK 
 
Escherichia coli merupakan sejenis bakteria yang sering digunakan untuk 
tujuan pengendalian, manipulasi and ekspresi gen sasaran. Ekspresi gen-gen tertentu 
secara efisien, terutama yg berasal dari mamalia seringkali terhalang kerana 
kekurangan biomolekul-biomolekul tertentu seperti tRNA, telah menyebabkan 
penghasilan protein berkualiti dari E. coli dalam kuantiti yang sedikit. Bagi 
menyelesaikan masalah ini, suatu vektor plasmid pembantu yang mengandungi gen 
tRNA yang jarang telah digunakan dalam E. coli. Proses penyelenggaraan dua vector 
plasmid yang berbeza: untuk penghasilan protein sasaran dan juga tRNA jarang juga 
boleh menyebabkan pertambahan pada beban metabolik pada E. coli dan 
mengakibatkan pertumbuhan E. coli terencat dan pengurangan dalam penghasilan 
protein sasaran. Bagi menangani masalah ini, kami pernah mengubahsuai suatu 
vektor plasmid bagi mengekspresi protein sasaran dan juga menghasilkan tRNA 
jarang secara serentak. Walaubagaimanapun, kehadiran tapak-tapak enzim 
endonuklese yang dikendaki di dalam gen sasaran telah menjejaskan proses 
pengeklonan gen-gen ini secara efektif. Untuk tujuan ini, kami telah mengubasuai 
suatu vektor plasmid yang mampu menghasilkan gen-gen tRNA jarang dengan 
modul pengeklonan T/A bagi memudahkan pengeklonan gen-gen sasaran tanpa 
menggunakan sebarang enzim endonuklase. Kerja-kerja pembangunan vektor 
plasmid yang novel ini bertujuan untuk melengkapkan vektor plasmid ini dengan: a) 
modul pengeklonan T/A bagi mempercepatkan proses pengeklonan gen bebas 
xi 
 
enzim endonuklase, b) tiga gen tRNA jarang bagi meningkatkan penghasilan protein 
sasaran dengan lebih efisien, c) kawalatur penghasilan protein yang ketat, dan d) 
suatu gabungan hexahistidine tag pada C terminal protein sasaran bagi memudahkan 
pengasingan dan rekombinan protein yang tulen. 
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DEVELOPMENT OF A NOVEL T/A CLONING AND EXPRESSION 
VECTOR FOR EFFICIENT EXPRESSION OF PROTEIN-BASED 
BIOPHARMACEUTICALS IN Escherichia coli. 
 
 
ABSTRACT 
 
Escherichia coli is one of the most popular bacterial hosts for handling, 
manipulating, and expressing target genes of interest. Certain genes are difficult 
to express, often due to scarcity of specific tRNA. This has led to little and/or 
poor quality protein production in E. coli.  To alleviate this problem, E. coli hosts 
are transformed with rare tRNA-expressing helper plasmid vectors. 
Maintenance of two different plasmid vectors-expressing the gene of interest 
and rare tRNA genes exert metabolic burden on the host that may result in 
diminished growth and reduced protein production. To address this issue, we 
have previously engineered an expression vector that simultaneously expresses 
rare tRNA genes and the gene of interest. Restriction enzymes are frequently 
used to clone desired genes into plasmid vectors. However, the presence of 
restriction enzymes–recognition sites within the desired gene would hamper 
the cloning process. To this end, we have engineered a rare tRNA vector with a 
T/A cloning module to facilitate restriction enzyme-independent cloning of 
genes. This work has resulted in the development of a novel expression vector 
that featured: a) T/A cloning module for rapid and restriction enzyme–
independent cloning; b) three rare tRNA genes for efficient expression of 
therapeutic proteins; c) a tightly regulated and inducible promoter for 
controlled expression of the desired gene; and d) a C-terminal hexahistidine tag 
for rapid purification of recombinant protein. 
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CHAPTER 1: INTRODUCTION 
1.1 DNA recombination technology is an integral tool for the protein 
research 
For the past decades, protein research has survived many challenges. One of 
the biggest challenges faced by the protein research scientists is to amass 
kilogrammes of animal and plant tissues for extraction of various proteins of interest. 
Previously, this practice was a norm in order to meet the requirements for adequate, 
valid and reproducible data analysis(Fakruddin, Mohammad Mazumdar, Bin 
Mannan, Chowdhury, & Hossain, 2013; Rosano & Ceccarelli, 2014). These valuable 
proteins, oftentimes occur at a very low amount, even in their native sources, and the 
work to recover these proteins generally translate into labour-, time- and cost-
inefficiency (Ferrer-Miralles, Domingo-Espín, Corchero, Vázquez, & Villaverde, 
2009). Therefore, scientists are turning their focus onto alternative protein production 
system for a guaranteed unlimited supply, robustness, superior economic value and 
represent the certain desired biochemical or biological activity of the native protein 
(Duilio, Tutino, & Marino, 2004; Henry & Xiaoming, 2012; Kielkopf, Bauer, & 
Urbatsch, 2012; Nordlund et al., 2008; Palomares, Estrada-Mondaca, & Ramírez, 
2004).  
Synthetic heterologous production of the recombinant protein of interest was 
made possible with the debut of recombinant DNA technology (Fakruddin et al., 
2013). The advent of genome sequencing technology has enabled scientist to identify 
the specific gene that encodes for their valuable proteins. Coupled with the 
sequencing technology, enormous DNA and protein sequencing data has been 
gathered. The information gathered is proponent in answering some of the most 
fundamental questions in biology, so a parallel high-throughput DNA recombinant 
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method development is increasingly in high demand (Meiering & Aravind, 2016). 
High-throughput DNA recombinant methods allowed the debut of numerous 
heterologous expression systems. These systems were developed to satisfy the need 
of various protein manipulations for identification and purification, enhanced and 
effective protein production, protein profiling analysis for biochemical, structural, 
mutation and functional studies (Schumann & Ferreira, 2004; Ventura & Villaverde, 
2006). In turn, the availability of such feats propelled the realisation of these valuable 
protein into biotherapeutics development (Schumann & Ferreira, 2004). 
The production of the recombinant protein is a multistep and straightforward 
process (Matsumura, 2015). The production of the desired recombinant protein begin 
by assembling a recombinant DNA. A piece of gene of interest is cloned into an 
expression vector plasmid, and the recombinant DNA product, in the form of 
plasmid, is transformed into expression host of choice, induced and the protein is 
ready for recovery, purification and characterization (Rosano & Ceccarelli, 2014). 
So, the DNA recombinant is considered as the central element for the heterologous 
protein production. 
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1.2 Common challenges in DNA recombination 
The advancement of sequencing technology for the past decade in decoding 
various complex eukaryotic and prokaryotic genome has yielded an enormous 
amount of information (Reisinger, Kern, Fesko, & Schwab, 2007; C. Wang et al., 
2013). However, assortment of genes that encodes for valuable proteins that have 
been identified by bioinformatics applications is yet to be studied (Reisinger et al., 
2007). This is due to the suboptimal DNA recombination method that did not favour 
for multiple heterologous gene assembly in automation format.  
The introduction of polymerase chain reaction (PCR), where the in vitro 
amplification of DNA, mediated by DNA polymerase and primed with synthetic 
oligonucleotide primers, in presence of deoxynucleotide triphosphates mix, amplifies 
the desired gene fragment from the DNA template. The PCR allowed easy and rapid 
isolation of desired genes of interest from the genome of their natural sources (Jeung 
et al., 2002). Thus, the debut of advanced sequencing technologies, coupled with 
PCR technology has helped propel the need for a rapid, easy and high throughput 
DNA recombination technology to manipulate and express various target genes of 
interest on a large scale.  
The most challenging part of assembling a recombinant DNA is when the 
method is subjected to various individual optimisations in order to develop an 
efficient and effective DNA recombination protocol. Oftentimes, the optimisations 
are exclusive for a particular vector-target DNA construct and require method re-
optimization for another set of DNA construct. Optimisations are subjected to 
experimental failures and troubleshooting which translates into countless repetitions 
(Matsumura, 2015). Not only that, the cost of pursuing research resources, especially 
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the technical labour, far exceeded the marginal variable costs of reagents used in 
molecular cloning (Matsumura, 2015; C. Wang et al., 2013). 
The traditional method of DNA recombination relies on restriction enzyme  
digestion and ligation of DNA in order to assemble a recombinant DNA 
(Zimmermann et al., 1998). This restriction enzyme-mediated recombination is often 
limited by the presence of the restriction sites within both the gene of interest and the 
destination plasmid vector (C. Wang et al., 2013). Although this pitfall can be 
overcame by incorporation of unique and at times, exotic restriction enzyme 
recognition sites in both the target DNA and plasmid vector via PCR, this may prove 
expensive (Reisinger et al., 2007). However, this approach is only applicable if the 
desired restriction enzyme sites are absent within the amplified sequence (Jeung et 
al., 2002; Reisinger et al., 2007). Moreover, the selection of suitable restriction 
enzyme sites for recombination has become more limited with increased sizes of the 
amplified sequences (Gengyo-Ando, Yoshina, Inoue, & Mitani, 2006). 
Even if the aforementioned pitfalls are embraced, the use of multiple 
enzymes for restriction digestion and the ligation of the both vector and target DNA 
can lead to increased time consumption and at experimental expenses (S. Chen, 
Songkumarn, Liu, & Wang, 2009). In addition, this method requires multiple 
purifications and/or enzymatic modifications steps in order to ensure a successful 
DNA recombination (Zhou & Gomez-Sanchez, 2000).     
All these problems can potentially cause a bottleneck within the stream of 
protein research work and deny an effective and efficient workflow to manipulate 
and express various target genes of interest (C. Wang et al., 2013). Therefore, an 
easy, high throughput, rapid alternative DNA recombination technology is in need. 
This is because the high-throughput DNA recombination technologies, especially 
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those that favours automation are the answer to effective and efficient workflow for 
the study of various target genes of interest. 
 
1.3 T/A cloning improves the DNA recombination methodology 
The development of new cloning techniques are always driven by the 
attempts to improvise the existing restriction enzyme- and ligase-mediated 
recombination (Matsumura, 2015). This traditional method still remains relevant 
until today, as it is well-described, easily monitored and troubleshoot methodology. 
However, the fact that the traditional method is notoriously known to be resistant 
towards high-throughput settings (Berlec & Štrukelj, 2012; Goda, Tenno, Takasu, 
Hiroaki, & Shirakawa, 2004) it is relatively unsuitable for large-scale manipulation 
and expression of various target genes of interest. 
Performing DNA recombination using PCR amplimers always remained a 
challenge in molecular biology labs. This is because, during the PCR amplification 
process, more than half of the amplimers have 3' A-tails, the by-product of template-
independent manner of terminal deoxytransferase activity of Taq DNA polymerase 
enzyme (Jeung et al., 2002). The presence of an extra nucleotide at the termini of the 
PCR amplimers can hamper an efficient DNA recombination process. In blunt-ended 
DNA ligation, both vector and insert are required to be blunt-ended, thus presence of 
an extra nucleotide can post the risk of inefficient DNA recombination process 
(Dimov, 2012). 
This phenomenon may render the blunt-ended DNA ligation technique 
inefficient (Dimov, 2012). A potential solution to this problem is to perform termini-
polishing using a Klenow fragment or exonuclease enzyme prior to ligation. 
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However, this method may incur additional costs, labour intensive and time-
consuming (Dimov, 2012). 
This phenomenon has given birth to the development of 3'T-tailed linearized 
plasmid vector (T-vector) that is able to accept the 3‟A-tailed PCR amplimers 
(Gengyo-Ando et al., 2006; Matsumura, 2015). This method, also known as the T/A 
cloning, was first described by Holton and Graham in 1991, taps into the terminal 
deoxynucleotidyl transferase activity of Taq DNA polymerase to create a 3'A-
overhang onto the PCR amplimers and can easily be ligated with complementary T-
vectors without the need of any modifications (Green, M.R. and Sambrook, 2012; 
Holton & Graham, 1991; Matsumura, 2015). Figure 1.1 illustrates the DNA 
recombination using T/A cloning method.  
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Figure 1.1 DNA recombination using T/A cloning method.  
The T/A cloning method requires a linear 3‟T-tailed plasmid vector (T-vector) to be 
aligned with a compatible 3‟A-tailed gene fragment. The terminal deoxynucleotidyl 
transferase activity of a Taq DNA polymerase enzyme during PCR amplification 
caused a non-templated addition of a single deoxyadenosine triphosphate (dATP) 
onto the 3‟ termini of the PCR amplimers. The 3‟A-tailed PCR amplimers can easily 
be cloned into a T-vector without the need of any restriction enzyme digestion and/or 
termini modifications. The DNA nick at the T/A junctions can be ligated by using a 
DNA ligase and propagated in an E. coli host. 
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The T/A cloning method is by far, the simplest and most efficient DNA 
recombination method that allows direct cloning of PCR amplimers without the use 
of restriction enzymes, designer recombinase enzymes or topoisomerases for site-
specific recombination (C. Wang et al., 2013). Any plasmid vector can be made into 
a T-vector regardless of the existing restriction enzyme sites, plus direct cloning of 
PCR amplimers made the T/A cloning a suitable candidate to be developed into a 
high-throughput setting.  
Another advantage of the T/A cloning method is this method can be adapted 
for various downstream DNA recombination applications, not exclusively for 
modification and expression of target genes. For example, the T/A cloning method 
has been appreciated to study various genes and gene regulatory components 
(Fujimori, 2009; Gengyo-Ando et al., 2006; Yu et al., 2014), novel strategy for site-
directed mutagenesis (Adachi & Fukuhara, 2012), transient eukaryotic expression 
and reporter vector (C. Wang et al., 2013), adapted to create a hybrid Gateway-T/A 
cloning method (Miles & Verkade, 2014), in vivo RNAi gene functional assay 
(Kamath & Ahringer, 2003), and many more. 
In comparison to other alternative recombination methods, T/A cloning is 
superior to Gateway and Creator cloning systems because the latter require multistep 
recombination processes. Although both Gateway and Creator cloning systems are 
independent of restriction enzymes and ligases, the multistep recombination is time- 
and labour-intensive, their designer recombinases are expensive and require long and 
deliberate primer design which often complicates the gene cloning and has proven to 
be cost-inefficient in a high-throughput application (C. Wang et al., 2013). 
The ligation independent cloning method (LIC), however, suffers from long 
primers (C. Wang et al., 2013), enzymatic processing of DNA termini (Zhou & 
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Gomez-Sanchez, 2000) and requires an intermediate plasmid before being cloned 
into a destination vector (Reisinger et al., 2007). 
The T/A cloning technology, alike any other alternative cloning methods, 
also comes with its own limitations and requires a deeper understanding of its nucleic 
acid biochemistry and proper optimisations in order to be effective and efficient 
(Matsumura, 2015). Moreover, this technique relies entirely upon the terminal 
deoxynucleotidyl transferase activity of Taq DNA polymerase and/or terminal 
transferase enzyme and subsequent ligation (Matsumura, 2015). So suboptimal 
enzymatic condition of these enzymes would greatly hamper efficient and effective 
DNA recombination via T/A cloning.  
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1.4 Challenges in T/A cloning methodology and potential solutions 
Alike any other DNA recombination method, a selection system is essential to 
identify individual clones which harbour the gene recombinant from the self-ligating 
plasmid. Although theoretically self-ligation of T-vector is impossible due to 
incompatible termini, such phenomena can happen (due to the loss of either or both 
overhanging „T‟) and the presence of self-ligating vector plasmid would hinder an 
efficient T/A DNA recombination (Dimov, 2012).  
Successful DNA recombination can be screened by α-complementation method. This 
method of screening for positive clones required association of two inactive 
fragments of E. coli β-galactosidase to form a functional enzyme. The desired gene 
usually cloned into the plasmid multiple cloning sites caused the production of the 
amino acid terminal fragment which is incapable of forming a functional enzyme. So 
only bacterial colonies which harbour a functional β-galactosidase will appear blue in 
the presence of chromogenic X-Gal (Green & Sambrook, 2012a). Ideally, only white 
colonies should harbour the recombinant DNA. 
The α-complementation method is only applicable for cloning desired gene in the 
form of plasmid DNA. This is because of the gene regulatory elements of an 
expression plasmid could be hampered by the presence of the native gene regulatory 
elements in α-complementation. So, this method is only limited to cloning of the 
desired gene. Furthermore, the α-complementation method of screening DNA 
recombinant is not completely infallible. The outcome of the α-complementation can 
often be affected by the size of the insert, mutational changes within the plasmid 
(Green & Sambrook, 2012a), and culture environment (C. Wang et al., 2013). 
The introduction of lethal gene ccdB cassette into the cloning site of T-vector as 
stuffer would alleviate this problem (C. Wang et al., 2013). The desired gene of 
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interest is supposed to replace this gene during DNA recombination assembly. This 
gene is widely used as a potent negative selection marker for Gateway cloning, 
whereby the clones with plasmid DNA vector which harbours the ccdB gene will not 
survive leaving only clones possessing the desired DNA recombinant to thrive. 
However, the use of ccdB is not economical because only special strains can be used 
to propagate the T-vector harbouring the ccdB gene as a stuffer.  
The success of T/A cloning depends upon the generation of the T-vector. There are 
various methods described to prepare the T-vector including T-tailing by terminal 
deoxytransferase activity of Taq DNA polymerase and/or terminal transferase 
enzymes or restriction endonuclease treatment (Reisinger et al., 2007). The earlier 
method requires linearization of the vector, termini-polishing and addition of 3‟T-
tails by Taq DNA polymerase or terminal transferase enzyme with the presence of 
excess dTTPs (Dimov, 2012; Goda et al., 2004; Jeung et al., 2002).   
However, this method is considered to be less efficient than the latter due to the low 
efficiency of the terminal transferase enzyme to include a single dTTP onto the 3' 
ends of the linearized plasmid (Jeung et al., 2002). Moreover, it is difficult to 
monitor and regulate the polymerase and exonuclease activities. The multistep 
process of incorporating the 3‟T-overhangs is often labour- and time-inefficient 
especially for a standalone lab (Dimov, 2012). 
Alternatively, the T-vector can be synthesised by restriction digestion processing 
which undeniably yields a single 3‟T-tail (Dimov, 2012). This method typically 
requires an inverse PCR amplification to linearize and flank the cloning site with 
desired restriction enzyme. A careful primer design is important to ensure the 
generation of a 3‟T-tail after the restriction enzyme processing and a correct frame is 
maintained. 
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The XcmI enzyme is one of the regular restriction enzymes of choice for the 
generation of 3'T-tails. The restriction processing generates a single 3‟ overhang 
within its recognition sequence 5‟-CCANNNNN/NNNNTGG-3‟ (where N represents 
either A, T, C, or G). The idea is to incorporate two XcmI restriction enzyme sites 
flanking the plasmid cloning site or flanking a stuffer fragment., The T-vector is 
generated by simply restricting the plasmid vector with XcmI restriction enzyme 
(Dimov, 2012).  
However, XcmI often suffers from partial cleavage resulting in a relatively high 
background of empty plasmid when cloning and requires introducing a XcmI-
containing cassette which limits the flexibility in terms of site of the PCR product 
integration and requires plasmid modification. (Berlec & Štrukelj, 2012)  
Alternatively, AhdI restriction enzyme can also be used to generate the 3‟T-
overhangs. AhdI is often a preferred restriction enzyme for this purpose due to its 
superiority in restriction enzyme efficiency compared to XcmI (Dimov, 2012; 
Reisinger et al., 2007). Moreover, its shorter restriction enzyme recognition sequence 
made it less complicated to be included in the vector via PCR amplification (Dimov, 
2012).  
The only downside of adopting AhdI restriction enzyme to generate the T-vector is 
this enzyme is not suitable for cloning vectors of variants and descendants of the 
pUC family due to the presence of secondary AhdI site within the Amp
R
 gene. This 
problem can be easily resolved by introducing a silent mutation onto the secondary 
AhdI site via site-directed mutagenesis (Adachi & Fukuhara, 2012; Dimov, 2012; 
Jeung et al., 2002; Stevenson & Brown, 2015). Other available enzymes that can be 
used to create 3‟ overhangs include AspEI (Goda et al., 2004; Jeung et al., 2002), 
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HphI (Jeung et al., 2002; C. Wang et al., 2013), Eam1105I (Goda et al., 2004), AspEI 
and MboII (Jeung et al., 2002), BciVI, BfiI, MnlI and TaaI (C. Wang et al., 2013). 
The most critical downside of the T/A cloning is that it is unsuitable for cloning and 
construction of expression library due to its bi-directional gene insert cloning (Goda 
et al., 2004). The basis of T/A cloning method is in the formation of a single, 
bilateral 3'overhangs and this caused the population of the hybridised intermediates 
of vector-insert complexes to be equal in both directions. Although Goda et al (2004) 
has successfully developed an asymmetrical AhdI whereby correctly oriented insert 
will generate NcoI/NdeI restriction enzyme sites within the AhdI site, T/A cloning is 
still insufficient to be adapted for construction of libraries due to inability to enrich 
the correctly oriented ligated target gene. 
Due to its bidirectional cloning nature of the T/A cloning method, this cloning 
strategy is often adopted for recombination of the target gene fragment into a cloning 
plasmid rather than into an expression plasmid vector. We observed that most 
literature published in 2017 explores the applicability of the T/A cloning method 
within the vicinity of cloning and propagation of the target DNA, compared to 
cloning the target DNA into T/A-adapted expression vectors (D. J. Lee, Lee, Jang, 
Ferrandon, & Lee, 2017; K.-L. Lee et al., 2017; Mattes & Escalante-Semerena, 2016; 
Ota et al., 2017; Shi et al., 2017; Zhang et al., 2016). There are a handful of T/A and 
T/A-variant cloning and expression kits available in the market, with impressive 
claims that each product is faster, cheaper and more efficient, but there is no 
guarantee that the technique or enzyme-catalysed reaction is 100% efficient or 
specific especially when placed under suboptimal conditions. Therefore, it is 
imperative for any method to be optimised empirically and a proper monitoring at 
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each stage of DNA recombination to ensure an uninterrupted workflow in protein 
research studies. 
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1.5 Problem statement 
The simplicity of the T/A cloning method, and adaptability of the 3‟T-
overhangs cloning site onto any plasmid vector are the two strong points that made 
this cloning strategy among the most adopted cloning method.  
Despite the versatility and simplicity of the T/A cloning method, the 
aforementioned pitfalls have hindered the potential of the T/A cloning method to be 
adapted into a high-throughput system. Here, we reported a number of improvements 
to the existing T/A cloning methodology and by adapting our T/A cloning 
technology onto our pSA-RIL expression plasmid. 
The pSA-HNef-C6His-RIL plasmid was previously developed by our 
colleague to improve the expression of HIV-1 Nef protein which formerly was 
expressed at very low concentrations in soluble form in E. coli expression system 
(Mualif et al., 2015). We have identified that the presence of codons rarely used by 
E. coli was the reason behind low yields of soluble HIV-1 Nef protein. To address 
this issue, we included a selection of rare tRNA genes within the HIV-1 Nef 
expression plasmid. The co-expression of an array of tRNA genes (argU, ileY and 
leuW) significantly improved the yields of soluble HIV-1 Nef protein.  
Realising the potential of this expression plasmid for the expression of genes 
rich in codons rarely used by E. coli, we replaced the HIV-1 Nef gene with a multiple 
cloning site (MCS) polylinker to create pSA-MCS-RIL plasmid in view to make the 
process of desired heterologous gene recombinant easier. However, the MCS 
contains a limited number of restriction enzyme sites. To overcome this problem, a 
deliberate primer design must be made to include a new, non-existing restriction 
enzyme site onto the target genes for in-frame cloning into the pSA-MCS-RIL 
plasmid vector. The incorporation of the new restriction enzyme sites to the target 
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gene and/or plasmid vector and the subsequent restriction enzyme digestion and 
purification further complicates the cloning process, and may potentially hamper an 
efficient and high-throughput gene recombination. 
Thereby, we attempted to improve the cloning methodology of the pSA-RIL 
plasmid by incorporating our T/A cloning module to replace the existing MCS. Our 
T/A cloning module was specifically designed to allow (1) directional cloning of 
PCR amplimers by the incorporation of asymmetrical AhdI sites and (2) low false-
positive plasmid background by incorporating the lethal sacB gene. 
This thesis describes: 
1. The engineering of the pSATA-RIL cloning/expression plasmid vector and its 
plasmid vector derivatives. 
2. Evaluation of the pSATA-RIL cloning/expression plasmid vector by 
expressing sacB and CAT genes. 
This is a proof-of-concept study that demonstrates an improved cloning and 
expression method of pSATA-RIL plasmid from the pSA-MCS-RIL plasmid. The 
findings described in this thesis are the provisional assessment for an improved T/A 
cloning methodology. 
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1.6 Objective statement 
Based on the works of literature cited above, we hypothesised that the 
incorporation of our T/A cloning module onto pSA-RIL vector would improve the 
heterologous gene cloning methodology for protein expression in E. coli system. 
 
The objectives of this study are: 
1. To design a T/A cloning module to the cloning site of the pSA-RIL plasmid 
and incorporate a lethal sacB gene as a stuffer gene into creating pSATA-
sacB-RIL cloning/expression plasmid vector 
2. To evaluate the pSATA-RIL cloning/expression plasmid vector by expressing 
sacB and CAT genes. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals/reagents 
Refer to Appendix A for the list of Chemicals/reagents used in this study. 
2.1.2 Consumables 
Refer to Appendix B for the list of Consumables used in this study. 
2.1.3 Culture media 
Refer to Appendix C for culture media used in this study. 
2.1.4 General buffers, stock solutions, antibiotics 
Refer to Appendix D for general buffers, stock solutions and antibiotics. 
2.1.5 Bacterial strains 
Refer to Appendix E for the list of bacterial strains. 
2.1.6 Plasmids 
Refer to Appendix F for the list of plasmids used in this study. 
2.1.7 Primers 
Refer to Appendix G for the list of primers used in this study. 
2.1.8 General instruments 
Refer to Appendix H for the list of general instruments used in this study. 
2.1.9 DNA restriction digestion enzymes 
Refer to Appendix I for the list of DNA restriction digestion enxymes used in this 
study. 
2.1.10 DNA ligation  
Refer to Appendix J for the protocol for DNA ligation. 
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2.2 Experimental Strategy 
The present study was divided into three parts: (1) the construction of a T/A 
cloning and expression plasmid vector, (2) the optimisation of the site-directed 
mutagenesis method and the sequences of the spacer spanned between the Shine-
Dalgarno (SD) and the ATG start codon, and finally (3) the cloning and expression of 
levansucrase and chloramphenicol acetyltransferase enzyme. Figure 2.1 illustrates 
the outline process workflow for the present study. 
 
 
Figure 2.1 Outline process workflow for the present study.  
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2.3 Methods 
2.3.1 Bacterial strains and culture conditions 
In this present study, we utilised E. coli strain NEB 5-alpha for plasmid 
propagation, strain NEB T7 Express for expression of cloned insert DNA, and strain 
Agilent Technologies XL10-Gold ultracompetent cells for mutagenic plasmid 
propagation. All cells were maintained on LB agar without any antibiotic and 
routinely propagated in LB broth without any antibiotic supplementations. The 
selection of clones with various vectors was done in LB medium supplemented with 
ampicillin (100 μg/mL). 
All bacterial strains were maintained on LB agar with appropriate supplements and 
temporarily stored at 4  C.  ubculturing was done once every 14 days. 
 
2.3.2 General primer design 
The primers used in this study was designed based on the sequence of the 
target gene. In silico design of the primers was done by using Vector NTI software 
and the primer DNA sequences were sent to Biobasic Inc. Canada for the 
oligonucleotide synthesis. The primers were synthesised using Perkin-Elmer DNA 
synthesiser. The primers were purified by polyacrylamide gel electrophoresis 
(PAGE) at 50 nm scale. 
 
2.3.3 Polymerase Chain Reaction (PCR) amplification 
The PCR amplification of the target genes requires a basic PCR reaction mix 
and thermocycler setting. For initial PCR amplification, we adhered to the 
recommended protocols by the suppliers and further modification of the reaction 
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components and/or thermocycler settings were introduced as necessary. A typical 1× 
PCR master mix for a total reaction of 50 μL in a PCR tube was prepared as below: 
A 25 µL of 5× KAPA HotStart Buffer (to final 1×) was added to a PCR tube. 
25 mM MgCl2 was added to final 1.5 mM, 10 mM dNTP mix was added at final 0.2 
mM of each dNTP. 10 mM of „sense‟ and „antisense‟ primers was added to final 0.5 
µM each. 5 U/µL KAPA Taq DNA polymerase was added into the tube to final 1 U. 
The DNA template was added as required to final 200 ng and pyrogen-free water 
was added to final volume of 50 µL.  
The components were prepared on ice and vortexed briefly. The KAPA Taq 
DNA polymerase was added in the last step. The PCR tube was placed on a 
thermocycler pre-set to 95˚C. A typical PCR thermocycler setting was set as follows: 
 The initial denaturation was set to 95°C for 5 minutes. Then a 30-temperature 
cycle was set: denaturation at 95°C for 30 seconds, annealing 50-56 (touchdown) or 
Tm-5°C for 30 seconds and extension at 72°C for 1 min per kb of amplimers. The 
final extension was performed at 72°C for 1 min per kb amplimers.  
We categorised the PCR reactions performed in this study based on the 
expected size of the amplimer, and the requirement for proofreading properties of 
DNA polymerase enzyme. 
 
2.3.3(a) Insert PCR 
This PCR reaction is used to amplify our desired target DNA (insert) for 
assembly of DNA recombinant. The typical size for this PCR reaction is between 
500 bp to 2 kb. We used KAPA HiFi HotStart DNA polymerase which was supplied 
in KAPA HiFi HotStart ReadyMix (2×) (Kapa Biosystems #KK2601) to catalyse the 
reaction. A typical insert PCR reaction is as follows: 
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A 25 µL 2× KAPA HiFi HotStart Ready Mix was added into a PCR tube to a 
final 1×. An equimolar 10µM „sense‟ and „antisense‟ primers was added to final 0.3 
µM each. 200 ng template DNA was added and finally pyrogen-free water was added 
to final volume of 50 µL. 
All the reaction mix was prepared on ice and vortexed briefly. The PCR tube 
was placed on a thermocycler pre-set to 95˚C. The PCR thermocycler setting was set 
as indicated in 2.3.3 Polymerase Chain Reaction (PCR) amplification. 
 
2.3.3(b) Whole plasmid (inverse) PCR 
This PCR reaction amplifies a segment of DNA between the two outward-
pointing primers. In this study, we performed the whole plasmid (inverse) PCR to 
flank our desired plasmid with the sequence of interest while maintaining the exactly 
same nucleotide sequence with the template plasmid. The typical size of this 
template is around 6 kb. Thus, a thermostable DNA polymerase with 3‟ to 5‟ 
exonuclease (proofreading) activity with the lowest error rate was required to 
catalyse this reaction. We used Q5
®
 DNA polymerase enzyme (NEB #M0491). A 
typical inverse PCR reaction is as below: 
 In a 50 µL reaction, 25 µL 5× Q5 Reaction buffer was added to final 1×, 
10mM dNTP mix was added to final 0.2 mM each, 10 µM „sense‟ and „antisense‟ 
primers was added to final 0.5 µM each. 200 ng DNA template was added and 2 
U/µL Q5 High-Fidelity DNA polymerase was also added to final 1 U. The pyrogen-
free water was added to final volume 50 µL. 
All the reaction mix was prepared on ice and vortexed briefly before adding 
the Q5 High-Fidelity DNA polymerase. The PCR tube was placed on a thermocycler 
pre-set to 98˚C. The PCR thermocycler setting was set as follows: 
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 The initial denaturation was set to 98°C for 30 seconds. Then a 25-
temperature cycle was set: denaturation at 95°C for 30 seconds, annealing 50-56 
(touchdown) or Tm-5°C for 30 seconds and extension at 72°C for 1 min per kb of 
amplimers. The final extension was performed at 72°C for 1 min per kb amplimers. 
 
2.3.3(c) Colony PCR 
A colony PCR is used to screen for the desired DNA recombinant from colonies of 
transformed E. coli strain. 
 
2.3.3(c)(i) Preparation of bacterial lysate 
Randomly selected transformant colonies with diameter around 2-3 mm was 
selected for the colony PCR screening. The single colony was aseptically picked with 
a micropipette tip and inoculated into 10 µL of pyrogen-free water in a sterile PCR 
tube. For identification purposes, the tip was streaked onto a patching grid plate.  The 
PCR tube was placed onto a heating block at 95˚C for about 2 minutes and 
centrifuged at 4,000×g for one minute. The supernatant was taken as a template for 
the colony PCR. 
 
2.3.3(c)(ii) Colony PCR 
This colony PCR is similar to insert PCR in terms of amplimer size but does 
not require any proofreading activity. We used KAPA Taq DNA polymerase which 
was supplied in 2× KAPA Taq ReadyMix with dye (Kapa Biosystems #KK1024). A 
typical colony PCR reaction was prepared as follows: 
A 25 µL 2× KAPA Taq Ready Mix was added into a PCR tube to a final 1×. 
An equimolar 10µM „sense‟ and „antisense‟ primers was added to final 0.2 µM each. 
 24 
 
200 ng template DNA was added and finally pyrogen-free water was added to final 
volume of 50 µL. 
All the reaction mix was prepared on ice and vortexed briefly. The PCR tube 
was placed on a thermocycler pre-set to 95˚C. The PCR thermocycler setting was set 
as indicated in 2.3.3 Polymerase Chain Reaction (PCR) amplification. 
 
2.3.4 Visualisation and quantification of DNA 
2.3.4(a) Agarose gel electrophoresis 
We used the agarose gel electrophoresis to resolve the DNA according to its 
size and to inspect, analyse and purify DNA fragments. 
 
2.3.4(a)(i) Preparation of agarose gel and sample loading 
A 0.7% (w/v) agarose gel was prepared by weighing 0.7 g agarose (BIO 
1000-500g) and added into 100 mL of 1× TAE buffer in a conical flask. The mixture 
was heated at medium/high power in a microwave oven for about 2 minutes until the 
agarose dissolved. The mixture was swirled gently to make sure there is no agarose 
clump visible before leaving to cool to about 45˚C. The tip of a sterile micropipette 
tip was used to dip into ethidium bromide (10 mg/mL) before added to the mixture. 
The flask was swirled gently to mix and poured into a pre-fixed plastic gel cast fitted 
with an appropriate gel comb. The bubbles were carefully removed by using a sterile 
micropipette tip and the gel was allowed to solidify at room temperature for 30 
minutes. 
 
